EA201890647A1 - Лечение нейродегенеративных заболеваний - Google Patents
Лечение нейродегенеративных заболеванийInfo
- Publication number
- EA201890647A1 EA201890647A1 EA201890647A EA201890647A EA201890647A1 EA 201890647 A1 EA201890647 A1 EA 201890647A1 EA 201890647 A EA201890647 A EA 201890647A EA 201890647 A EA201890647 A EA 201890647A EA 201890647 A1 EA201890647 A1 EA 201890647A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- signaling pathway
- treatment
- neurodegenerative diseases
- methods
- myd88
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1516905.5A GB201516905D0 (en) | 2015-09-24 | 2015-09-24 | Treatment of Neurodegenerative diseases |
| PCT/GB2016/052970 WO2017051188A1 (en) | 2015-09-24 | 2016-09-23 | Treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890647A1 true EA201890647A1 (ru) | 2018-09-28 |
Family
ID=54544061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890647A EA201890647A1 (ru) | 2015-09-24 | 2016-09-23 | Лечение нейродегенеративных заболеваний |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180263992A1 (OSRAM) |
| EP (1) | EP3352759A1 (OSRAM) |
| JP (1) | JP6893917B2 (OSRAM) |
| KR (1) | KR20180056695A (OSRAM) |
| CN (1) | CN108025005A (OSRAM) |
| AU (1) | AU2016329005A1 (OSRAM) |
| BR (1) | BR112018005855A2 (OSRAM) |
| CA (1) | CA2999390A1 (OSRAM) |
| EA (1) | EA201890647A1 (OSRAM) |
| GB (1) | GB201516905D0 (OSRAM) |
| MA (1) | MA42930A (OSRAM) |
| MX (1) | MX2018003619A (OSRAM) |
| WO (1) | WO2017051188A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170335324A1 (en) | 2014-11-12 | 2017-11-23 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
| GB201714316D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatement of neurodegenerative diseases |
| GB201714307D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714311D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714303D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| CN108853111B (zh) * | 2018-08-07 | 2020-06-05 | 浙江大学 | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN113694047A (zh) * | 2021-08-31 | 2021-11-26 | 杭州师范大学 | β-石竹烯在制备抗肿瘤药物中的应用 |
| WO2025152803A1 (zh) * | 2024-01-17 | 2025-07-24 | 四川大学 | 一种靶向traf6的多肽及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US62342A (en) * | 1867-02-26 | Improved tool for the manufacture of paper bags | ||
| US257403A (en) * | 1882-05-02 | Electric lighting apparatus | ||
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US20030232741A1 (en) * | 2002-05-06 | 2003-12-18 | Washington University | Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway |
| JP4328500B2 (ja) * | 2002-07-25 | 2009-09-09 | 独立行政法人農業・食品産業技術総合研究機構 | 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品 |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| WO2004092154A1 (en) * | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| DK1714960T3 (en) * | 2004-02-09 | 2018-07-16 | Mitsubishi Tanabe Pharma Corp | NEW THERAPEUTIC MEDICINE FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) OR DISEASE AScribed |
| DK1848414T3 (da) * | 2005-02-03 | 2011-07-25 | Gen Hospital Corp | Fremgangsmåde til behandling af gefitinib-resistent cancer |
| US7449442B2 (en) * | 2005-07-12 | 2008-11-11 | Children's Medical Center Corporation | EGFR inhibitors promote axon regeneration |
| JP2008061505A (ja) * | 2006-09-04 | 2008-03-21 | Hisamitsu Pharmaceut Co Inc | 筋萎縮性側索硬化症の治療剤のスクリーニング方法 |
| WO2010017541A2 (en) * | 2008-08-08 | 2010-02-11 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
| AU2010281524A1 (en) * | 2009-08-06 | 2012-02-23 | Neuraltus Pharmaceuticals, Inc. | Treatment of macrophage-related disorders |
| WO2011050192A1 (en) * | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Modulation of axon degeneration |
| BR112015001838B1 (pt) * | 2012-07-27 | 2022-10-25 | Izumi Technology, Llc | Composição de inibidor de efluxo |
-
2015
- 2015-09-24 GB GBGB1516905.5A patent/GB201516905D0/en not_active Ceased
-
2016
- 2016-09-23 CN CN201680056062.1A patent/CN108025005A/zh active Pending
- 2016-09-23 WO PCT/GB2016/052970 patent/WO2017051188A1/en not_active Ceased
- 2016-09-23 BR BR112018005855A patent/BR112018005855A2/pt not_active Application Discontinuation
- 2016-09-23 MX MX2018003619A patent/MX2018003619A/es unknown
- 2016-09-23 CA CA2999390A patent/CA2999390A1/en not_active Abandoned
- 2016-09-23 MA MA042930A patent/MA42930A/fr unknown
- 2016-09-23 US US15/762,657 patent/US20180263992A1/en not_active Abandoned
- 2016-09-23 EP EP16775842.4A patent/EP3352759A1/en not_active Withdrawn
- 2016-09-23 JP JP2018516056A patent/JP6893917B2/ja not_active Expired - Fee Related
- 2016-09-23 EA EA201890647A patent/EA201890647A1/ru unknown
- 2016-09-23 KR KR1020187010855A patent/KR20180056695A/ko not_active Withdrawn
- 2016-09-23 AU AU2016329005A patent/AU2016329005A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018005855A2 (pt) | 2018-10-16 |
| GB201516905D0 (en) | 2015-11-11 |
| KR20180056695A (ko) | 2018-05-29 |
| MA42930A (fr) | 2018-08-01 |
| EP3352759A1 (en) | 2018-08-01 |
| JP6893917B2 (ja) | 2021-06-23 |
| CN108025005A (zh) | 2018-05-11 |
| WO2017051188A1 (en) | 2017-03-30 |
| MX2018003619A (es) | 2018-08-01 |
| US20180263992A1 (en) | 2018-09-20 |
| CA2999390A1 (en) | 2017-03-30 |
| JP2018534259A (ja) | 2018-11-22 |
| AU2016329005A1 (en) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890647A1 (ru) | Лечение нейродегенеративных заболеваний | |
| JOP20220243A1 (ar) | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة | |
| MX2023015185A (es) | Degradadores de proteinas y usos de los mismos. | |
| EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
| EA201991553A1 (ru) | (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды | |
| SV2018005614A (es) | Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| EA201890051A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MA46098A (fr) | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r | |
| EP3760625C0 (en) | BICYCLIC LACTAMS AS PROTEIN KINASE 1 (RIP1) INHIBITORS INTERACTING WITH RECEPTORS FOR TREATMENT E.G. OF INFLAMMATORY DISEASES | |
| EA201792229A1 (ru) | Ингибиторы бромодомена | |
| EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
| MX2015012056A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
| MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
| MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| MX365864B (es) | Inhibidores de bromodominio biciclicos novedosos. | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| JOP20210158A1 (ar) | مُعَدِّلات التعبير الجيني عن hsd17b13 | |
| MX2022012386A (es) | Compuestos inhibidores de metaloenzimas. | |
| MX375737B (es) | Imidazopirazinonas como inhibidores de pde1. | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| MX390320B (es) | Farmaco de combinacion. |